As we close out 2025, we’re feeling proud of our accomplishments and energized by the opportunities ahead.
As the medical device clinical research industry faces evolving business consolidation, shifting client expectations, and increasing regulatory complexity, we remain intentional about scaling our business without losing what makes it special: Our people, our culture, and our commitment to doing clinical research the right way—#researchdonebright
Here are a few reflections on another great year!
Scaling with Intention
If there’s one thing that keeps me thoughtful (and occasionally up at night), it’s the challenge of scaling what has worked so well for nearly two decades and not diluting the “Bright Difference.” This year, Bright continued to grow—in revenue, headcount, scope, and responsibility—and just as importantly, we did so in a deliberate and mindful manner.
The CRO industry still struggles with turnover and burnout. In 2025, we aimed to continue to support and retain our exceptional talent at Bright. Our approach included:
- Investing in key functional leadership roles that strengthen the foundation of the business and allow our team to do their best work.
- Setting clear expectations and providing regular feedback to all team members.
- Encouraging the pursuit of meaningful professional development and certifications.
- Delivering cross-functional learning to deepen our business, therapeutic, and device-specific expertise.
Not only did we retain talent, we also attracted experienced, values-aligned professionals with fresh ideas. Highlights include:
- Expanding our Quality leadership to support a growing team, diverse project portfolio, and evolving regulatory expectations.
- Establishing dedicated roles in Marketing and Client Engagement to reflect how you and our clients engage with us in long-term strategic partnerships, not only as a service provider.
- Continuing to grow our CRA and Study Lead teams to ensure we maintain the depth, responsiveness, and consistency our clients deserve.
Behind the scenes, further investments in infrastructure are elevating our quality system and training programs and optimizing clinical systems and office platforms; this and collaboration with external advisors and auditors enhance Bright’s continuous improvement attitude. These investments allow us to meet the needs of our team and the high standards of our clients and regulators.
Happy Team, Happy Clients
Bright’s investments in our team paid off, leading to many client “wins” in 2025. Several medical device development programs we supported this year obtained regulatory market authorizations for their investigational products. Others had their significant progress toward that goal featured as headline data at major medical conferences, including TCT.
These achievements reinforce the importance of implementing strong clinical strategy and execution to demonstrate technologies are safe and effective. This also resulted in repeat business, expanded statements of work, and referrals, all of which are incredibly meaningful indicators of our 2025 success. Thank you to all who made those possible.
This year alone, clients asked Bright to:
- Broaden the scope of work from a single service offering to include multiple services or even full study management.
- Step in earlier to advise on study design and regulatory pathway strategy.
- Support complex studies under real-world pressure and timelines.
- Rescue their study from another CRO that couldn’t meet their expectations.
This trust is earned. It reflects years of consistently meeting (and exceeding!) expectations, communicating clearly, and providing an unwavering focus on quality. In 2026, we look forward to delivering that same exceptional value to you, whether you are a new business or a satisfied returning client.
Conclusion
At the end of the day, Bright’s success isn’t measured in growth or revenue. Our true success comes from our contributions to public health: Partnering with clients who trust us to play a critical role in developing medical devices that change lives. Ensuring safe and effective products are used by physicians and patients depends on supporting data from well-run clinical trials with scientifically sound designs. In short, seeing these contributions makes our team feel proud of the work they’re doing and keeps us going forward.
Thank you to our clients, partners, and the Bright team for another exceptional year. Our future is bright – and we look forward to sharing another year with you. Wishing you continued success and a wonderful year ahead.
